Cargando…

Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases

Pathological complete response is achievable with mFOLFOX6 plus cetuximab therapy for unresectable colorectal cancer with multiple paraaortic lymph node metastases (mCRC) despite right-sided colonic origin. A 62-year-old woman with synchronous paraaortic lymph node metastases of transverse colon can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suetsugu, Tomonari, Matsuhashi, Nobuhisa, Takahashi, Takao, Tanahashi, Toshiyuki, Matsui, Satoshi, Imai, Hisashi, Tanaka, Yoshihiro, Yamaguchi, Kazuya, Yoshida, Kazuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256093/ https://www.ncbi.nlm.nih.gov/pubmed/30546885 http://dx.doi.org/10.3892/mco.2018.1742

Ejemplares similares

Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report
por: Tokumaru, Yoshihisa, et al.
Publicado: (2019)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)

Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
por: Oki, Eiji, et al.
Publicado: (2019)

Thoracoscopic subtotal esophagectomy via a right thoracic cavity approach to treat an intractable fistula after 20 months from onset of an idiopathic esophageal rupture: A case report
por: Imai, Takeharu, et al.
Publicado: (2019)

A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer
por: Matsuhashi, Nobuhisa, et al.
Publicado: (2018)

Local recurrence of T1a rectal cancer following radical endoscopic mucosal resection: A case report
por: Matsumoto, Keita, et al.
Publicado: (2018)

Intranodal lymphangiography for chyle leakage after esophagectomy: A case report
por: Suetsugu, Tomonari, et al.
Publicado: (2020)

Safety and feasibility of laparoscopic intersphincteric resection for a lower rectal tumor
por: Matsuhashi, Nobuhisa, et al.
Publicado: (2017)

Safety and feasibility of laparoscopic intersphincteric resection for a lower rectal tumor
por: Matsuhashi, Nobuhisa, et al.
Publicado: (2018)

Feasibility of the Reconstruction with Fascia Lata Patch on the Abdominal Wall Defect After Resection of the Abdominal Desmoid Tumor
por: Goto, Ayana, et al.
Publicado: (2020)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Recent advancements in esophageal cancer treatment in Japan
por: Tanaka, Yoshihiro, et al.
Publicado: (2018)

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer
por: Zhao, Shen, et al.
Publicado: (2022)

Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients
por: Sugimoto, Shinichi, et al.
Publicado: (2009)

Long-term stable disease with mFOLFOX6 chemotherapy plus cetuximab for bone marrow metastasis from rectal cancer: A case report
por: Fan, Xiumei, et al.
Publicado: (2023)

Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma
por: Cai, Zhiyuan, et al.
Publicado: (2021)

Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma
por: Shamseddine, Ali, et al.
Publicado: (2020)

Subtotal stomach in esophageal reconstruction surgery achieves an anastomotic leakage rate of less than 1%
por: Yoshida, Kazuhiro, et al.
Publicado: (2020)

Single-incision laparoscopic ileocecal resection in a 10-year-old child with appendiceal neuroendocrine tumor
por: Goto, Ayana, et al.
Publicado: (2019)

Laparoscopic technique and safety experience with barbed suture closure for pelvic cavity after abdominoperineal resection
por: Matsuhashi, Nobuhisa, et al.
Publicado: (2013)

Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma
por: Yang, Zhenyun, et al.
Publicado: (2023)

The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells
por: Mori, Ryutaro, et al.
Publicado: (2018)

A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma
por: Horimatsu, Takahiro, et al.
Publicado: (2017)

Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer
por: Li, Guodong, et al.
Publicado: (2021)

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
por: Kato, Junko, et al.
Publicado: (2016)

Retracted: Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

The long-term survival of stage IV gastric cancer patients with conversion therapy
por: Yamaguchi, Kazuya, et al.
Publicado: (2017)

Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

A case report on efficacy of Abound™ for anti-EGFR antibody-associated skin disorder in metastatic colon cancer
por: Matsuhashi, Nobuhisa, et al.
Publicado: (2014)

Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma
por: Shamseddine, Ali, et al.
Publicado: (2020)

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
por: Borelli, Beatrice, et al.
Publicado: (2018)

Risk and early predictive factors of anastomotic leakage in laparoscopic low anterior resection for rectal cancer
por: Fukada, Masahiro, et al.
Publicado: (2019)

Novel therapy for locally advanced triple-negative breast cancer
por: YAMADA, ATSUKO, et al.
Publicado: (2015)

Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study
por: He, Min-Ke, et al.
Publicado: (2017)

Acute Myocardial Infarction Due to Coronary Artery Embolism during Chemotherapy with mFOLFOX-6 Plus Bevacizumab for Metastatic Colon Cancer
por: Aoshima, Hiroyuki, et al.
Publicado: (2022)

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study
por: Pernot, Simon, et al.
Publicado: (2020)

A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report
por: Sonoda, Hiromichi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pjop9g2uqtqidr4vbijikk2k3e